Premier Alternatives

Cardurion

Biotechnology · Burlington, MA · Founded 2017 · Privately Held (backing)

Developer of cardiovascular therapeutics intended to treat cardiovascular diseases. Cardurion is based in Burlington, MA and was founded in 2017. Its last known valuation is $760 million. It has raised $622 million across 1 recorded round; the latest was a $260 million Series B in Jul 2024.

Last price · $/share
—
Implied valuation
$760.0M
Total raised
$621.8M
Last round
Later Stage VC (Series B)
Jul 2024

Cardurion key facts

  • Developer of cardiovascular therapeutics intended to treat cardiovascular diseases.
  • Cardurion’s last known valuation is $760.0M.
  • It has raised $621.8M across 1 recorded rounds; the latest was Later Stage VC (Series B) ($260.0M) in Jul 2024.
  • Notable investors include Fidelity Management & Research Company, GV, New Enterprise Associates, Blue Owl Capital, Bain Capital — 16 tracked in total.
  • Status: Privately Held (backing).
Free account
More of Cardurion with a free account
  • ·The complete investor list: 16 names
  • ·Watch Cardurion: the Monday email on marks, rounds and moves
Create free account
No card required

Membership and data by Private Market View

Cardurion funding rounds

1 rounds
Jul 2024Later Stage VC (Series B)$260.0M▮
Full funding history →

Cardurion valuation

Cardurion's last known valuation is $760 million. The figure stands until a priced round, a secondary trade or an institutional fund mark prices the stock again.

How much has Cardurion raised?

Cardurion has raised $622 million in total; 1 of its rounds is on record. The largest on record was a $260 million Series B in Jul 2024.

Cardurion investors

16 investors are on record for Cardurion, including Fidelity Management & Research Company, GV, New Enterprise Associates and Blue Owl Capital. By type, the record holds 6 venture capital firms, 2 hedge funds and 2 private equity firms. The Series B in Jul 2024 drew 11 investors.

Comparable companies

Comparable biotechnology names by valuation on PrivateMarketView: DNA Script ($660 million), Odyssey Therapeutics ($638 million) and bit.bio ($546 million).

About Cardurion

Developer of cardiovascular therapeutics intended to treat cardiovascular diseases. The company's therapeutics offer advanced novel mechanisms to develop new treatments for heart diseases, causing morbidity and mortality, enabling healthcare professionals to prevent arrhythmia disorders and heart failures.

Industry
Biotechnology
Sector
Healthcare
HQ
Burlington, MA, United States
Founded
2017
Employees
50
Ownership
Privately Held (backing)

Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.

Valuation on record
$760.0M

Cardurion’s last known valuation. A PrivateMarketView mark is published once fund marks, secondary prints or a priced round let us confirm it.